CLINICAL_TRIALS
trial_result
· 2022-02-24
Clinical Trial Update: The Effect of Horizant (Gabapentin Enacarbil) on Augmentation [NA]
Summary
A completed clinical trial evaluating the effect of Horizant (gabapentin enacarbil) on augmentation in restless legs syndrome. Results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Missouri-Columbia | Conditions: Restless Legs Syndrome | NA | Status: COMPLETED | Results posted: 2022-02-24